

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) A peptide consisting of ~~an amino acid sequence of~~ SEQ ID No:1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, or 17.
2. (Canceled)
3. (Currently amended) ~~An inducer~~ tumor antigen ~~of cytotoxic T lymphocytes~~, wherein the ~~inducer~~ tumor antigen consists ~~essentially~~ of a peptide of claim 1.
4. (Canceled)
5. (Withdrawn) A method for inducing cytotoxic T lymphocytes using the peptide of claim 1.
6. (Canceled)
7. (Canceled).
8. (Canceled).
9. (Withdrawn) A polynucleotide encoding the peptide of claim 1, or its complementary strand.
10. (Canceled)
11. (Withdrawn) A polynucleotide that hybridizes with the polynucleotide or its complementary strand of claim 9 under a stringent condition.
12. (Canceled)

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

13. (Withdrawn) A recombinant vector comprising the polynucleotide and/or its complementary strand of claim 9.

14. (Canceled)

15. (Withdrawn) A recombinant vector comprising the polynucleotide and/or its complementary strand of claim 11.

16. (Canceled)

17. (Withdrawn) A transformant transformed with the recombinant vector of claim 13.

18. (Canceled)

19. (Withdrawn) A transformant transformed with the recombinant vector of claim 15.

20. (Canceled)

21. (Withdrawn) A method for producing a peptide, which comprises the step of culturing the transformant of claim 17.

22. (Canceled)

23. (Withdrawn) A method for producing a peptide, which comprises the step of culturing the transformant of claim 19.

24. (Canceled)

25. (Withdrawn) An antibody that immunologically recognizes the peptide of claim 1.

26. (Canceled)

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

27. (Withdrawn) A method for screening a compound that interacts with the peptide of claim 1 and enhances the recognition property by at least one of HLA-A2402-restricted cytotoxic T lymphocytes or HLA-A2-restricted cytotoxic T lymphocytes, wherein said method comprises contacting said peptide with said compound to determine said recognition property.

28. (Canceled)

29. (Withdrawn) A method for screening a compound that interacts with the polynucleotide of claim 9 and enhances the expression wherein said method comprises contacting said polynucleotide with said compound to determine said expression.

30. (Canceled)

31. (Withdrawn) A method for screening a compound that interacts with the polynucleotide of claim 11 and enhances the expression wherein said method comprises contacting said polynucleotide with said compound to determine said expression.

32. (Canceled)

33. (Withdrawn) A method for screening a compound that interacts with the recombinant vector of claim 13 and enhances the expression wherein said method comprises contacting said recombinant vector with said compound to determine said expression.

34. (Canceled)

35. (Withdrawn) A method for screening a compound that interacts with the recombinant vector of claim 15 and enhances the expression wherein said method comprises contacting said recombinant vector with said compound to determine said expression.

36. (Canceled)

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

37. (Withdrawn) A method for screening a compound that interacts with the transformant of claim 17 and enhances the expression wherein said method comprises contacting said transformant with said compound to determine said expression.

38. (Canceled)

39. (Withdrawn) A method for screening a compound that interacts with the transformant of claim 19 and enhances the expression wherein said method comprises contacting said transformant with said compound to determine said expression.

40. (Canceled)

41. (Withdrawn) A method for screening a compound that interacts with the peptide of claim 1 and enhances the recognition property by at least one of HLA-A2402-restricted cytotoxic T lymphocytes or HLA-A2-restricted cytotoxic T lymphocytes, wherein said method comprises contacting the transformant, which is transformed with recombinant vector comprising polynucleotide encoding said peptide, with said compound to determine said recognition property.

42. (Canceled)

43. (Withdrawn) A compound obtained by the screening method according to claim 27.

44. (Currently amended) A pharmaceutical composition comprising an effective amount for cancer treatment of at least one peptide selected from a peptide of claim 1.

45. (Canceled)

46. (Withdrawn) A pharmaceutical composition comprising an effective amount for cancer treatment of at least one selected from the polynucleotides of claim 9.

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

47. (Canceled)

48. (Withdrawn) A pharmaceutical composition comprising an effective amount for cancer treatment of at least one selected from the polynucleotides of claim 11.

49. (Canceled)

50. (Withdrawn) A pharmaceutical composition comprising, an effective amount for cancer treatment of at least one selected from the recombinant vectors of claim 13.

51. (Canceled)

52. (Withdrawn) A pharmaceutical composition comprising, an effective amount for cancer treatment of at least one selected from the recombinant vectors of claim 15.

53. (Canceled)

54. (Withdrawn) A pharmaceutical composition comprising, an effective amount for cancer treatment of at least one selected from the transformants of claim 17.

55. (Canceled)

56. (Withdrawn) A pharmaceutical composition comprising, an effective amount for cancer treatment of at least one selected from the transformants of claim 19.

57. (Canceled)

58. (Withdrawn) A method for treating cancer comprising applying to a patient the inducer of cytotoxic T lymphocytes of claim 3.

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

59. (Canceled)

60. (Canceled)

61. (Canceled)

62. (Withdrawn) A method for treating cancer comprising applying to a patient the pharmaceutical composition of claim 44.

63. (Canceled)

64. (Withdrawn) A method for treating cancer comprising applying to a patient the pharmaceutical composition of claim 46.

65. (Canceled)

66. (Withdrawn) A method for treating cancer comprising applying to a patient the pharmaceutical composition of claim 48.

67. (Canceled)

68. (Withdrawn) A method for treating cancer comprising applying to a patient the pharmaceutical composition of claim 50.

69. (Canceled)

70. (Withdrawn) A method for treating cancer comprising applying to a patient the pharmaceutical composition of claim 52.

71. (Canceled)

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

72. (Withdrawn) A method for treating cancer comprising applying to a patient the pharmaceutical composition of claim 54.

73. (Canceled)

74. (Withdrawn) A method for treating cancer comprising applying to a patient the pharmaceutical composition of claim 56.

75. (Canceled)

76. (Withdrawn) The method of claim 58, wherein lymphocytes of said patient are treated with said inducer in vivo.

77. (Withdrawn) The method of claim 58, wherein lymphocytes of said patient are treated with said inducer in vitro.

78. (Canceled)

79. (Canceled)

80. (Canceled)

81. (Canceled)

82. (Canceled)

83. (Canceled)

84. (Withdrawn) The method of claim 62, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vivo.

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

85. (Withdrawn) The method of claim 62, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vitro.

86. (Canceled)

87. (Canceled)

88. (Withdrawn) The method of claim 64, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vivo.

89. (Withdrawn) The method of claim 64, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vitro.

90. (Canceled)

91. (Canceled)

92. (Withdrawn) The method of claim 66, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vivo.

93. (Withdrawn) The method of claim 66, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vitro.

94. (Canceled)

95. (Canceled)

96. (Withdrawn) The method of claim 68, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vivo.

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

97. (Withdrawn) The method of claim 68, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vitro.

98. (Canceled)

99. (Canceled)

100. (Withdrawn) The method of claim 70, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vivo.

101. (Withdrawn) The method of claim 70, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vitro.

102. (Canceled)

103. (Canceled)

104. (Withdrawn) The method of claim 72, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vivo.

105. (Withdrawn) The method of claim 72, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vitro.

106. (Canceled)

107. (Canceled)

108. (Withdrawn) The method of claim 74, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vivo.

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

109. (Withdrawn) The method of claim 74, wherein lymphocytes of said patient are treated with said pharmaceutical composition in vitro.

110. (Canceled)

111. (Canceled)

112. (Withdrawn) A reagent kit for use in the method for screening a compound that interacts with the peptide of claim 1 and enhances the recognition property by at least one of HLA-A2402-restricted cytotoxic T lymphocytes or HLA-A2-restricted cytotoxic T lymphocytes, wherein said reagent kit includes at least one or more peptide(s) according to claim 1.

113. (Withdrawn) A reagent kit for use in the method for screening a compound that interacts with the peptide of claim 1 and enhances the recognition property by at least one of HLA-A2402-restricted cytotoxic T lymphocytes or HLA-A2-restricted cytotoxic T lymphocytes, wherein said reagent kit includes at least one or more polynucleotide(s) which encodes the peptide according to claim 1.

114. (Withdrawn) A reagent kit for use in the method for screening a compound that interacts with the peptide of claim 1 and enhances the recognition property by at least one of HLA-A2402-restricted cytotoxic T lymphocytes or HLA-A2-restricted cytotoxic T lymphocytes, wherein said reagent kit includes at least one or more recombinant vector(s) comprising the polynucleotide which encodes the peptide according to claim 1.

115. (Withdrawn) A reagent kit for use in the method for screening a compound that interacts with the peptide of claim 1 and enhances the recognition property by at least one of HLA-A2402-restricted cytotoxic T lymphocytes or HLA-A2-restricted cytotoxic T lymphocytes, wherein said reagent kit includes at least one or more transformant(s) transformed with the recombinant vector comprising polynucleotide which encodes the peptide according to claim 1.

U.S. Patent Application No. 10/062,257
Amendment After Final dated August 20, 2007
Reply to Office Action of May 18, 2007

116. (Withdrawn) A reagent kit for use in the method for screening a compound that interacts with the peptide of claim 1 and enhances the recognition property by at least one of HLA-A2402-restricted cytotoxic T lymphocytes or HLA-A2-restricted cytotoxic T lymphocytes, wherein said reagent kit includes at least one or more antibody(s) that immunologically recognizes the peptide according to claim 1.

117. (Canceled)

118. (Canceled)

119. (Canceled)

120. (Canceled)

121. (Canceled)

122. (Withdrawn) A reagent kit for use in the method for screening a compound that interacts with the polynucleotide which encodes the peptide according to claim 1 and enhances the expression of said peptide, wherein said reagent kit includes at least one or more polynucleotide (s) which encodes the peptide according to claim 1.

123. (Canceled)